Holdings
EQ/T.Rowe Price Health Sciences Portfolio
As of Jun 30, 2026, EQ/T.Rowe Price Health Sciences Portfolio reported 161 positions worth US$175M. Largest: Eli Lilly And Company, Johnson & Johnson and Unitedhealth Group Incorporated. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Eli Lilly And Company | 21,120 | US$25.3M | +3,500 | Jun 30, 2026 |
| Johnson & Johnson | 44,072 | US$11.2M | +27,937 | Jun 30, 2026 |
| Unitedhealth Group Incorporated | 25,398 | US$10.6M | +7,102 | Jun 30, 2026 |
| Abbvie Inc. | 37,236 | US$9.37M | +15,965 | Jun 30, 2026 |
| Merck & Company, Inc. | 58,349 | US$7.5M | +12,353 | Jun 30, 2026 |
| Gilead Sciences, Inc. | 41,362 | US$5.23M | +10,925 | Jun 30, 2026 |
| Thermo Fisher Scientific Inc | 9,404 | US$4.71M | −3,941 | Jun 30, 2026 |
| Vertex Pharmaceuticals Incorporated | 8,487 | US$4.22M | −317 | Jun 30, 2026 |
| Bristol-myers Squibb Company | 68,555 | US$3.95M | new | Jun 30, 2026 |
| Abbott Laboratories | 39,200 | US$3.56M | new | Jun 30, 2026 |